This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rilotumumab

Amgen, Inc.

Drug Names(s): AMG 102

Description: AMG 102 is a fully human monoclonal antibody that inhibits the action of hepatocyte growth factor (HGF)/scatter factor (SF). HGF/SF signaling through its receptor c-Met appears to play an important role in many types of human cancers. Thus, inhibition of the HGF/c-Met pathway with AMG 102 may slow or stop tumor growth and metastasis.

Deal Structure: Amgen and Astellas: Japan Alliance
In May 2013, Amgen and Astellas announced that the companies have entered into a strategic alliance to provide new medicines to help address serious unmet medical needs of Japanese patients. The first element of the alliance is a long-term collaboration between the two companies that will focus on the co-development and co-commercialization in Japan of five Amgen pipeline medicines. The second element of the alliance is the establishment of a Tokyo-based joint venture company through which the companies will work together to enable Amgen to rapidly build on-the-ground capabilities in Japan. The joint venture will operate under the name Amgen Astellas BioPharma KK.

Partners: Astellas Pharma, Inc.


Rilotumumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug